Total Synthesis of (−)-Muraymycin D2 and Its Epimer
- 9 February 2010
- journal article
- review article
- Published by American Chemical Society (ACS) in The Journal of Organic Chemistry
- Vol. 75 (5) , 1366-1377
Abstract
Full details of the first total synthesis of (−)-muraymycin (MRY) D2 and its epimer, the antibacterial nucleoside natural product, are described. Key strategic elements of the approach include the preparation of the urea dipeptide moiety found in the muraymycins containing an l-epi-capreomycidine via a nitrene C−H insertion of the sulfamate 10 and the fully protected muraymycin skeleton at a late stage by an Ugi four-component reaction. Thus, the nitrene C−H insertion of the sulfamate 10 with 10 mol % of Rh2(esp)2 catalyst gave the cyclic sulfamates 11a and 11b in 47% yield (11a:11b = 1:2.0). Construction of the cyclic guanidine skeleton was effected through the HgBr2-promoted cyclization of 42 followed by desulfonylation upon acetolysis of the oxathiazinane ring to give 43 in good yield. The amine obtained by selective removal of the Cbz group of the alcohol 44 was reacted with MeSC(═O)-l-Val-O-t-Bu (38) to provide 45, which was oxidized to the carboxylic acid 46. Reaction of 46, isonitrile 51, isovaleraldehyde, and 2,4-dimethoxybenzylamine furnished the desired Ugi products, the final deprotection of which successfully afforded (−)-MRY D2 and epi-MRY D2 (53) after HPLC separation of the diastereomers. This approach would afford ready access to a range of analogues simply by altering each component.Keywords
This publication has 48 references indexed in Scilit:
- Drugs for bad bugs: confronting the challenges of antibacterial discoveryNature Reviews Drug Discovery, 2006
- Unmet medical needs in antibacterial therapyBiochemical Pharmacology, 2006
- Antibacterial drug discovery—Then, now and the genomics futureBiochemical Pharmacology, 2006
- Bad Bugs Need Drugs: An Update on the Development Pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of AmericaClinical Infectious Diseases, 2006
- Antibiotics: Where did we go wrong?Drug Discovery Today, 2005
- Artificial Neural Networks and Linear Discriminant Analysis: A Valuable Combination in the Selection of New Antibacterial CompoundsJournal of Chemical Information and Computer Sciences, 2004
- Where will new antibiotics come from?Nature Reviews Microbiology, 2003
- Structure-Based Classification of Antibacterial ActivityJournal of Chemical Information and Computer Sciences, 2002
- Getting Discriminant Functions of Antibacterial Activity from Physicochemical and Topological ParametersJournal of Chemical Information and Computer Sciences, 2001
- Antimicrobial Activity Characterization in a Heterogeneous Group of CompoundsJournal of Chemical Information and Computer Sciences, 1998